Understanding what happens in cardiac tissue after a heart attack has entered a new level of molecular resolution — and the implications extend far beyond the acute event. The senescence-associated secretory phenotype, or SASP, turns out to orchestrate a complex, time-stamped biological program that can either rescue or permanently damage the post-infarction heart, depending on when and where it is active.
This review synthesizes current evidence on how cardiac cells — including cardiomyocytes, fibroblasts, and endothelial cells — enter a state of permanent proliferative arrest following the ischemic insult of myocardial infarction, and how the SASP they subsequently release reshapes the immune environment in a phase-specific manner. During the acute window, SASP factors amplify inflammation and recruit immune effector cells to clear necrotic debris. In the subacute phase, the same secretory machinery pivots toward inflammation resolution, extracellular matrix remodeling, and scar consolidation. By the chronic phase, however, persistent SASP activity drives pathological fibrosis, paracrine senescence spread to neighboring healthy cells, and progressive cardiac dysfunction. Spatially, the review delineates distinct SASP roles across the infarct core, the electrically vulnerable border zone, and the remote myocardium undergoing compensatory remodeling.
What makes this analysis particularly notable is the therapeutic framing: senescent cell elimination — via senolytics such as navitoclax or dasatinib-plus-quercetin — or SASP modulation through senomorphics represent an emerging intervention class that could be timed to the cardiac healing timeline. This is important because blanket senescent cell clearance during the subacute reparative phase could paradoxically worsen scarring. Timing the intervention to the chronic phase, when SASP becomes maladaptive, appears more rational. The review is comprehensive rather than a primary trial, so causality in humans remains incompletely established. Still, as an integrative framework mapping cellular senescence biology onto post-MI pathophysiology, this represents a meaningful conceptual advance for cardiac longevity research.
